OPEN LABEL EUROPEAN STUDY TO SUPPORT THE EARLY IDENTIFICATION OF PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN IN PRIMARY CARE AND TO ASSESS THE EFFECTIVENESS AND TOLERABILITY OF PREGABALIN IN THIS POPULATION

Femme et Homme

| Pays :
| Organes :
| Spécialités :

Extrait

To raise awareness and enhance the diagnosis of patients with chronic low back pain(CLBP) with a neuropathic pain component who are refractory to standard analgesic therapy and/or one treatment for neuropathic pain in a primary care setting and assess the effectiveness and tolerability of pregabalin in this group of patients. To assess patient satisfaction with treatment with pregabalin in patients with CLBP with a neuropathic pain component who are refractory to standard analgesic therapy and/or one treatment for neuropathic pain in a primary care setting.

Critère d'inclusion

Pregabalin (Lyrica ®) is approved in the European Union for the treatment of peripheral and central neuropathic pain in adults. The medical condition being investigated in this study is chronic neuropathic low back pain

Liens

ictrp
euctr
ictrp
euctr

Kusajili – Centralise les essais cliniques mondiaux

OPEN LABEL EUROPEAN STUDY TO SUPPORT THE EARLY IDENTIFICATION OF PATIENTS WITH CHRONIC NEUROPATHIC LOW BACK PAIN IN PRIMARY CARE AND TO ASSESS THE EFFECTIVENESS AND TOLERABILITY OF PREGABALIN IN THIS ...